Angela Di Paola, PhD
Postdoctoral AssociateAbout
Research
Publications
2026
Real-time peer-navigation support during community re-entry for adults with opioid use disorder
Tarfa A, Borker M, Lancaster M, Santiago R, Di Paola A, Frank C, Springer S. Real-time peer-navigation support during community re-entry for adults with opioid use disorder. Journal Of Substance Use And Addiction Treatment 2026, 183: 209903. PMID: 41548607, PMCID: PMC12895323, DOI: 10.1016/j.josat.2026.209903.Peer-Reviewed Original ResearchConceptsCriminal legal involvementCommunity re-entryOpioid use disorderUse disorderPeer navigatorsQualitative content analysisSocial service benefitsExtended-release naltrexoneMulti-site randomized controlled trialActive substance useParole officersExtended-release buprenorphineHousing managementXR-NTXCourt datesUnstable housingRandomized Controlled TrialsDirect servicesProvision of foodSubstance useLegal involvementAnalytical rigorFull-timeTreatment outcomesRe-entry
2025
A qualitative examination of barriers and facilitators to HIV prevention and treatment for people involved with the criminal justice system
Villaire S, Sease T, Pankow J, Bennett A, Pulitzer Z, Hansen L, Frank C, Di Paola A, Lehman W, Sanchez M, McQuaid A, Schultheis A, Stein B, Springer S, Nijhawan A, Knight K. A qualitative examination of barriers and facilitators to HIV prevention and treatment for people involved with the criminal justice system. Health & Justice 2025, 13: 37. PMID: 40478391, PMCID: PMC12143099, DOI: 10.1186/s40352-025-00344-6.Peer-Reviewed Original ResearchFocus groupsContext themesCommunity healthcare providersCriminal justice systemTrained qualitative researchersImplementation science frameworkMethodsSix focus groupsAudio-recorded interviewsNIDA-funded projectFocus group transcriptsDeductive coding strategiesDevelopment of interventionsFocus group processExamination of barriersSubstance use disorder preventionFocus group dataIntra-agency communicationPatient navigationPeer navigatorsCommunity serviceJustice systemIntervention implementationHIV careGroup transcriptsHealthcare providersInitiating Injectable Buprenorphine in People Hospitalized With Infections
Seval N, Roth P, Frank C, Di Paola A, Litwin A, Vander Wyk B, Neirinckx V, Schlossberg E, Lawson P, Strong M, Schade M, Nunez J, Levin F, Brady K, Nunes E, Springer S. Initiating Injectable Buprenorphine in People Hospitalized With Infections. JAMA Network Open 2025, 8: e2513000. PMID: 40445619, PMCID: PMC12125644, DOI: 10.1001/jamanetworkopen.2025.13000.Peer-Reviewed Original ResearchConceptsLong-acting buprenorphineOpioid use disorderReceipt of MOUDRandomized clinical trialsTAU armIntent-to-treat outcomesClinical trialsModerate to severe opioid use disorderSevere opioid use disorderProportion of patientsMultisite randomized clinical trialHospital settingStatistically significant differenceNursing case management servicesInfectious diseasesTAU groupMedian ageMedication management interventionCase management servicesInjectable buprenorphineHospitalization periodPrimary outcomeBaseline valuesInitiate MOUDMOUD receiptPilot Findings From the First Legalized Mobile Retail Pharmacy Clinic in the United States for Infectious Disease Treatment and Prevention Tailored to Reach People Who Use Drugs
Tarfa A, Di Paola A, Frank C, Schultheis A, Brooks R, Shenoi S, Springer S. Pilot Findings From the First Legalized Mobile Retail Pharmacy Clinic in the United States for Infectious Disease Treatment and Prevention Tailored to Reach People Who Use Drugs. Open Forum Infectious Diseases 2025, 12: ofaf200. PMID: 40276721, PMCID: PMC12019630, DOI: 10.1093/ofid/ofaf200.Peer-Reviewed Original ResearchHuman immunodeficiency virusHepatitis C virusOpioid use disorderAntiretroviral therapyViral loadHepatitis C virus viral loadTested HIVHuman immunodeficiency virus diagnosisSexually transmitted infection testingHepatitis C virus antibodyModerate to severe opioid use disorderDirect-acting antiviralsSevere opioid use disorderHIV antiretroviral therapyInfectious disease treatmentHCV VLImmunodeficiency virusPreexposure prophylaxisCommunity health workersPilot findingsC virusPostexposure prophylaxisHCV testingPositive testSubstance use disorders
2024
Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases
Parchinski K, Neirinckx V, Frank C, Di Paola A, Tarfa A, Shenoi S, Vander WyK B, Roth P, Ghantous T, Wegman M, Strong M, Levin F, Brady K, Nunes E, Litwin A, Springer S. Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases. Open Forum Infectious Diseases 2024, 11: ofae366. PMID: 39022389, PMCID: PMC11252843, DOI: 10.1093/ofid/ofae366.Peer-Reviewed Original Research
2023
Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians
Di Paola A, Farabee D, Springer S. Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians. Psychiatric Research And Clinical Practice 2023, 5: 78-83. PMID: 37711754, PMCID: PMC10499189, DOI: 10.1176/appi.prcp.20230022.Peer-Reviewed Original ResearchStimulant use disorderUse disordersSevere opioid use disorderMini International Neuropsychiatric InterviewDiagnostic assessmentOpioid use disorderDisorder assessmentInternational Neuropsychiatric InterviewDSM-IV criteriaHarm reduction interventionsNon-clinical staffTraditional diagnostic assessmentInternal consistencyDSM-5 versionValid measureOpioid dependenceOpioid misuseImmediate treatmentNeuropsychiatric InterviewOpioid epidemicDisorder modulesOverdose deathsReduction interventionsNon cliniciansRapid diagnosisCorrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]
Lier A, Seval N, Vander Wyk B, Di Paola A, Springer S. Corrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]. Journal Of Substance Use And Addiction Treatment 2023, 150: 209074. PMID: 37271717, DOI: 10.1016/j.josat.2023.209074.Commentaries, Editorials and LettersThe relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
Parchinski K, Di Paola A, Wilson A, Springer S. The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV. Drug And Alcohol Dependence Reports 2023, 7: 100159. PMID: 37159815, PMCID: PMC10163604, DOI: 10.1016/j.dadr.2023.100159.Peer-Reviewed Original ResearchOpioid use disorderExtended-release naltrexoneXR-NTXUse disordersKaplan-Meier survival analysisHIV viral suppressionMajor depressive disorderPublic health priorityOpioid cravingViral suppressionOpioid useHIV outcomesLife scoresRetrospective studyStudy baselineDepressive disorderOdds ratioDecrease recurrenceHealth prioritySurvival analysisPWHLifetime incarcerationStudy periodMean timeDisorders
2022
Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder
Lier A, Vander Wyk B, Di Paola A, Springer S. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. Open Forum Infectious Diseases 2022, 9: ofac624. PMID: 36467300, PMCID: PMC9709708, DOI: 10.1093/ofid/ofac624.Peer-Reviewed Original ResearchOpioid use disorderHepatitis C virusHCV treatment ratesHIV serostatusUse disordersHepatitis C virus (HCV) care cascadeHCV viral load testingTreatment ratesHCV treatment uptakeProspective cohort studyInjection drug useViral load testingGreater reductionDrug use frequencyHCV testingCare cascadeHCV antibodiesHIV screeningCohort studyHIV statusTreatment uptakeEntire cohortMedication treatmentC virusSerostatusAssociation between Prescribers’ Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability
Adzrago D, Di Paola A, Zhu J, Betancur A, Wilkerson J. Association between Prescribers’ Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability. Healthcare 2022, 10: 1733. PMID: 36141345, PMCID: PMC9498711, DOI: 10.3390/healthcare10091733.Peer-Reviewed Original ResearchOpioid use disorderSubstance use disordersUse disordersUse of MOUDUtilization of medicationsPharmacy professionalsLogistic regression analysisProfessionals' perceptionsMultinomial logistic regression analysisRisk ratio (RR) valuesOpioid treatmentMean ageMOUDPrescriber perceptionsMOUD servicesReplacement drugsSociodemographic characteristicsPatient accessibilityDisordersMedicationsPatientsRegression analysisMedical professionalsAbstinenceParticipants